Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
  • Subscribe
Submit An Article

Latest Articles

  • Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition
    Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition
    • News

  • In an age where celebs own tequila brands, this one owns a hangover cure
    In an age where celebs own tequila brands, this one owns a hangover cure
    • News

  • Markets continue to recover, commodities lead the charge overnight
    Markets continue to recover, commodities lead the charge overnight
    • Market Update

  • Pass go, collect mortgage: Why the Government’s latest first home buyer’s scheme is crap
    Pass go, collect mortgage: Why the Government’s latest first home buyer’s scheme is crap
    • Opinion

  • Crowd Media enters Silicon Valley partnership for interactive NFT collection
    Crowd Media enters Silicon Valley partnership for interactive NFT collection
    • News

  • MPower acquires Lakeland in $8m deal
    MPower acquires Lakeland in $8m deal
    • News

  • US market falls on Tech and Discretionary as Oil surges
    US market falls on Tech and Discretionary as Oil surges
    • Market Update

  • SportsHero launches eSports predictor in China to gamify eSports gambling
    SportsHero launches eSports predictor in China to gamify eSports gambling
    • News

  • This company is offering DNA tests for the whole family, including the dog!
    This company is offering DNA tests for the whole family, including the dog!
    • News

  • Regis Healthcare to claim back $14m spent on aged care COVID outbreaks
    Regis Healthcare to claim back $14m spent on aged care COVID outbreaks
    • News

MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms

  • In News
  • June 15, 2020
  • Alfred Chan
MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms

Health tech company MyFiziq (ASX: MYQ) has partnered with Canadian firm NuraLogix which will leverage the two company’s patented imaging technology. Using a smartphone camera, transdermal imaging and artificial intelligence (AI), the newly combined tech aims to determine a user’s probability of having COVID-19, as well as their risk of developing diseases that result in 70% of deaths globally. 

The Memorandum of Understanding (MoU) brings together MyFiziq’s existing smartphone screening technology and NuraLogix’s Transdermal Optical Imaging (TOI™) to extract blood flow information from a user’s face after taking a 30-second selfie video. 

Upon use of the non-invasive screening, users are provided with information about blood pressure, stress levels and heart rate amongst other parameters. Using this screening technology which is then processed by AI, the app can then offer an assessment on the user’s cardiovascular disease risk, diabetes risk and stroke risk which combine for 70% of global deaths annually. 

“This is an extremely exciting partnership for the companies. Bringing our technologies together will not only create a one of a kind solution, furthermore it will be unrivalled. Our offerings in a standalone environment have a deep patent suite,” said MyFiziq CEO, Vlado Bosanac. 

“When combining the company solutions, we form not only a unique offering, but one that enhances both companies’ ability to be the dominant player in digital health and convenience. The solutions form an easy to use, comprehensive review of an individual, accurately, privately, and conveniently from their mobile phone.

Beyond screening for the aforementioned disease risks, NuraLogix has been in collaboration with St. Michael’s Hospital, University of Toronto, and Zhongda Hospital in China to test symptom profiles of COVID-19 patients. Being developed into a smartphone app, NuraLogix is confident their imaging AI can determine the likelihood of a user having COVID-19 versus a seasonal flu or cold. 

The app will initially be trialed by The Serfaty Clinic in Brazil and WeSure/WeFit in China before MyFiziq looks to broaden distribution globally. 

Organisations around the world have been exploring the potential combination of thermal imaging cameras with drone technology to scan crowds as a measure in the fight against current and future pandemics.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition - May 18, 2022
  • SportsHero launches eSports predictor in China to gamify eSports gambling - May 17, 2022
  • Regis Healthcare to claim back $14m spent on aged care COVID outbreaks - May 16, 2022
  •  
  •  
  •  
  •  
  • ai
  • artificial intelligence
  • asx myq
  • coronavirus screening
  • health tech
  • medtech
  • MyFiziq
  • MYQ
  • Nuralogix
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition - May 18, 2022
  • SportsHero launches eSports predictor in China to gamify eSports gambling - May 17, 2022
  • Regis Healthcare to claim back $14m spent on aged care COVID outbreaks - May 16, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • Monash IVF joins M&A arms race with entry into Perth IVF market via acquisition - May 18, 2022
  • SportsHero launches eSports predictor in China to gamify eSports gambling - May 17, 2022
  • Regis Healthcare to claim back $14m spent on aged care COVID outbreaks - May 16, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

Copyright © 2020 The Sentiment. All rights reserved.